GlassScriptPhysician profile
Shealyn Berry
NPI 1407416548
$3,117.81
in general payments reported to CMS, 2019-2025
30 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,516 · 2022: $793 · 2023: $517 · 2024: $37.22 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $355.56 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $246.46 | 2021-2023 | |
| Glaxosmithkline, LLC. | $233.56 | 2021-2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $231.25 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $220.64 | 2021-2023 | |
| Novo Nordisk INC | $190.57 | 2021-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $171.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $165.65 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $164.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.22 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $123.27 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $114.24 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $112.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $100.53 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $85.38 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.89 | 2021-2022 | |
| Eisai INC. | $53.40 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $50.15 | 2022-2023 | |
| Dexcom, INC. | $46.90 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $45.62 | 2021 | |
| Lundbeck LLC | $41.48 | 2023 | Rexulti |
| Kyowa Kirin, INC. | $38.08 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.22 | 2021-2022 | |
| Organon LLC | $23.95 | 2025 | Nexplanon |
| Exact Sciences Corporation | $22.67 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.14 | 2022 | |
| Genentech USA, INC. | $13.18 | 2021 | |
| Astellas Pharma US INC | $12.04 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.65 | 2021 | |
| Sumitomo Pharma America, INC. | $11.52 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shealyn Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.